国际医学回复：您好，感谢您对公司的关注。公司本次向特定对象发行股票是基于长远发展战略作出的 审慎决策，已制定募集资金使用可行性分析报告。根据公司2025年12月3日披露的《2025年度向特定对 象发行股票预案》，本次募集资金总额不超过100,753.93万元，将主要用于智慧康养项目、质子治疗中 心二期项目以及补充流动资金。其中智慧康养项目总投资约7.51亿元，拟投入募集资金约6.38亿元，旨 在把握"银发经济"发展机遇，盘活公司存量资产；质子治疗中心二期项目总投资9993.13万元，拟投入 募集资金9993.13万元，旨在填补西北地区质子治疗市场空白；补充流动资金2.7亿元，旨在优化公司资 本结构，提高持续经营能力。公司本次向特定对象发行股票是顺应国家政策，基于公司发展战略作出的 主动选择，旨在把握行业发展机遇，优化资本结构，盘活存量资产，满足未来业务发展的资金需求，提 高持续经营能力。公司将持续规范运作，切实维护全体股东特别是中小股东的合法权益。谢谢！ 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 投资者提问：定增没有具体事实计 ...

广州医院质子中心四间质子治疗室已经全部启用，累计为550位患者提供质子治疗服务，单月新增患者 超过80人，服务能力持续提升。服务患者范围覆盖国内31个省级行政区以及20多个国家和地区，接受质 子治疗的患者年龄从1岁至91岁。2025年7月，广州医院质子中心完成了全国首例眼部脉络膜恶性黑色素 瘤质子治疗。 这一年期间，公司的质子治疗业务的稳步推进，进一步完善了公司在肿瘤精准治疗领域的布局，提升了 公司在高端医疗服务领域的核心竞争力。未来，公司将持续优化服务流程，提升诊疗效率，为更多肿瘤 患者提供优质、精准的质子治疗服务。 格隆汇12月30日丨 美中嘉和(02453.HK)公告，公司子公司广州泰和肿瘤医院质子治疗中心(以下简称"广 州医院质子中心")自2024年12月16日起至今，已正式运营一周年。公司高度重视质子治疗中心的临床能 力建设，坚持加强与国际先进医疗机构合作科研，与国际质子治疗技术同步发展，通过引进高端医疗人 才、加强技术研发与学术交流等方式，持续提升诊疗水平。截至目前，广州医院质子中心的临床服务能 力已得到充分验证，各项运营指标表现良好。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」）董事會（「董事 會」）自願刊發。 董事會欣然宣佈，本公司子公司廣州泰和腫瘤醫院質子治療中心（以下簡稱「廣州 醫院質子中心」）自2024年12月16日起至今，已正式運營一周年。公司高度重視 質子治療中心的臨床能力建設，堅持加強與國際先進醫療機構合作科研，與國際 質子治療技術同步發展，通過引進高端醫療人才、加強技術研發與學術交流等方 式，持續提升診療水平。截至目前，廣州醫院質子中心的臨床服務能力已得到充 分驗證，各項運營指標表現良好。 廣州醫院質子中心四間質子治療室已經全部啟用，累計為550位患者提供質子治 療服務，單月新增患者超過80人，服務能力持續提升。服務患者範圍覆蓋國內31 個省級行政區以及20多個國家和地區，接受質子治療的患者年齡從1歲至91歲。 2025年7月，廣州醫 ...

Core Viewpoint - International Medicine (000516.SZ) plans to raise up to 1.008 billion yuan through a private placement, focusing on three main areas: smart healthcare projects, proton therapy center phase II, and working capital supplementation [2][4] Group 1: Fundraising and Investment Focus - The fundraising will allocate 638 million yuan to smart healthcare projects, nearly 100 million yuan to the proton therapy center phase II, and 270 million yuan for working capital [2] - The smart healthcare project aims to utilize idle assets to "activate stock assets," responding to both policy demands and the need for asset revitalization [2][5] - The company intends to use 270 million yuan from the fundraising to meet operational funding needs and optimize its capital structure [2][5] Group 2: Financial Challenges - As of September 30, 2025, the company's debt-to-asset ratio reached 68.80%, significantly higher than the industry average, with a sharp decline in cash reserves from 1.52 billion yuan at the end of 2021 to 331 million yuan [4][7] - The company has substantial short-term borrowings of 995 million yuan and non-current liabilities due within a year totaling 905 million yuan, leading to a total of nearly 1.9 billion yuan in rigid debt due within a year [4] - The company has faced significant losses over the past four years, with cumulative losses reaching 2.621 billion yuan [7] Group 3: Market Opportunities and Strategic Adjustments - The company views the fundraising as a strategic adjustment to address market changes, financial pressures, and idle assets [3] - The smart healthcare project and proton therapy center phase II are seen as key initiatives to capitalize on the "silver economy" and high-end medical development opportunities [4][6] - The proton therapy center phase II aims to fill a market gap in the northwest region, where no proton therapy centers are currently operational [6] Group 4: Operational Efficiency and Cost Management - The company is attempting to improve operational efficiency through clinical pathway management and cost structure optimization [8][9] - As of the third quarter of 2025, the company reported a management expense ratio of 10.99%, a decrease from previous periods, indicating initial success in cost control [8] - The company plans to continue enhancing service quality and patient experience while exploring various specialized medical fields to build competitive advantages [9]

Core Viewpoint - The company, International Medicine, plans to raise up to 1.008 billion yuan through a private placement of shares, with the funds allocated for smart healthcare projects, the second phase of the proton therapy center, and to supplement working capital [1][2]. Group 1: Fundraising and Project Allocation - The fundraising will support the transition of the company's business from traditional medical services to high-end radiation therapy, establishing a synergistic business model of "comprehensive diagnosis + precise radiation therapy" [1]. - A significant portion of the raised funds will be directed towards the smart healthcare project, utilizing idle spaces to enhance asset utilization and generate high-value healthcare services [1]. - The second phase of the proton therapy center aims to establish the first operational proton therapy project in Northwest China [2]. Group 2: Financial Performance and Debt Management - The company has experienced substantial losses over recent years, with cumulative losses of 2.621 billion yuan from 2021 to 2024 [3]. - In the first three quarters of 2025, the company reported a revenue of 2.995 billion yuan, a year-on-year decline of 16.94%, and a net loss of 294 million yuan, representing a 38.45% increase in losses compared to the previous year [3]. - The company has a high debt ratio of 68.80%, and the fundraising is expected to help reduce this ratio and optimize the capital structure [1].

Core Insights - The Guangzhou Taihe Tumor Hospital Proton Therapy Center, under Meizhong Jiahe (02453.HK), ranked third in the "2024-2025 China Proton and Heavy Ion Center Rankings," highlighting its excellence in the field of proton therapy [1] Group 1: Rankings and Recognition - The ranking is based on a comprehensive indicator system centered around patient needs and operational excellence, developed with input from 21 experts with over 20 years of experience in radiation therapy [1] - The top two centers in the ranking are Shandong Provincial Tumor Hospital Proton Center and Shanghai Proton and Heavy Ion Hospital [1] Group 2: Equipment and Technology - Guangzhou Taihe Tumor Hospital is equipped with the latest Varian ProBeam proton therapy system, which offers advanced intensity-modulated proton therapy (IMPT) [2] - The superconducting cyclotron can accelerate proton beams to 60.84% of the speed of light, with a wide energy adjustment range for treating tumors at various depths [2] - The pencil beam scanning treatment head allows for precise irradiation with a minimum proton beam diameter of 3mm, minimizing damage to healthy tissue [2] Group 3: Medical Team and Clinical Capabilities - The medical team consists of leading experts in proton therapy, including key authors of the first "Proton and Heavy Ion Therapy Guidelines" in China, with extensive clinical and research experience [2] - The hospital has successfully treated a diverse patient population, with conditions ranging from nasopharyngeal cancer to pancreatic cancer, achieving significant treatment outcomes [3] Group 4: Compliance and Quality Control - The hospital adheres to strict compliance and quality control measures, guided by MD Anderson Cancer Center protocols and national clinical practice guidelines [3] - Comprehensive evaluations and assessments are conducted at every stage of treatment to ensure safety and quality in proton therapy applications [3] Group 5: Patient Experience - The hospital emphasizes a patient-centered service model, featuring case managers who provide detailed explanations of treatment processes and ongoing support throughout the treatment journey [4] - Post-treatment, case managers develop rehabilitation plans and conduct long-term follow-ups to ensure continuous health support for patients [4] Group 6: Future Outlook - The recognition of Guangzhou Taihe Tumor Hospital marks a significant milestone in its development and underscores Meizhong Jiahe's strong capabilities and strategic positioning in the oncology healthcare market [4] - The combination of advanced technology, expert teams, and growing market demand for high-end cancer treatment services positions Meizhong Jiahe for continued competitive advantage and growth opportunities [4]